ENOPH1 identified as key mediator of KRAS G12D/G13D-driven metabolic reprogramming

◇ RESEARCH

Preclinical research shows ENOPH1 is upregulated by the KRAS-MEK-ERK pathway and sustains oncogenic TGF-β/SMAD signaling, representing a potential therapeutic target in KRAS-mutant colorectal cancer. (International Immunopharmacology)